用于治疗非小细胞肺癌的新型KRAS抑制剂
Novel KRAS Inhibitors for Treating Non-small Cell Lung Cancer.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Jul 25;15(8):1201-1202. doi: 10.1021/acsmedchemlett.4c00342. eCollection 2024 Aug 8.
Abstract
Provided herein are novel KRAS inhibitors, pharmaceutical compositions, use of such compounds in treating non-small cell lung cancer, and processes for preparing such compounds.
摘要
本文提供了新型KRAS抑制剂、药物组合物、此类化合物在治疗非小细胞肺癌中的用途以及制备此类化合物的方法。
相似文献
1
Novel KRAS Inhibitors for Treating Non-small Cell Lung Cancer.用于治疗非小细胞肺癌的新型KRAS抑制剂
ACS Med Chem Lett. 2024 Jul 25;15(8):1201-1202. doi: 10.1021/acsmedchemlett.4c00342. eCollection 2024 Aug 8.
2
Novel 1,6-Naphthridine Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer.新型1,6-萘啶化合物作为SMARCA2抑制剂用于治疗非小细胞肺癌
ACS Med Chem Lett. 2025 Feb 14;16(3):371-372. doi: 10.1021/acsmedchemlett.5c00048. eCollection 2025 Mar 13.
3
1,6-Naphthridine Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer.作为治疗非小细胞肺癌的SMARCA2抑制剂的1,6-萘啶化合物
ACS Med Chem Lett. 2025 Mar 20;16(4):528-529. doi: 10.1021/acsmedchemlett.5c00128. eCollection 2025 Apr 10.
4
Novel Bicyclic Amines as CDK2 Inhibitors for Treating Metastatic Breast Cancer or Metastatic Lung Cancer.新型双环胺类化合物作为治疗转移性乳腺癌或转移性肺癌的细胞周期蛋白依赖性激酶2（CDK2）抑制剂
ACS Med Chem Lett. 2025 Jan 16;16(2):198-199. doi: 10.1021/acsmedchemlett.5c00005. eCollection 2025 Feb 13.
5
Novel Compounds as CDK2 Inhibitors for Treating Cancer.新型化合物作为治疗癌症的CDK2抑制剂
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
6
Novel MALT1 Inhibitors for Treating Cancer.用于治疗癌症的新型MALT1抑制剂
ACS Med Chem Lett. 2025 May 5;16(6):925-926. doi: 10.1021/acsmedchemlett.5c00229. eCollection 2025 Jun 12.
7
Novel PARP7 Inhibitors for Treating Cancer.用于治疗癌症的新型聚（ADP-核糖）聚合酶7抑制剂
ACS Med Chem Lett. 2025 Mar 20;16(4):526-527. doi: 10.1021/acsmedchemlett.5c00127. eCollection 2025 Apr 10.
8
MALT1 Inhibitors for Treating Cancer and Immunological Diseases.用于治疗癌症和免疫疾病的MALT1抑制剂
ACS Med Chem Lett. 2024 Aug 20;15(9):1419-1420. doi: 10.1021/acsmedchemlett.4c00390. eCollection 2024 Sep 12.
9
Pyrrolopyrazine Compounds as ERK5 Inhibitors for Treating Cancer.作为用于治疗癌症的细胞外信号调节激酶5（ERK5）抑制剂的吡咯并吡嗪化合物
ACS Med Chem Lett. 2024 Dec 11;16(1):16-17. doi: 10.1021/acsmedchemlett.4c00580. eCollection 2025 Jan 9.
10
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.作为用于治疗癌症的CD73抑制剂的新型双环杂环化合物。
ACS Med Chem Lett. 2024 Dec 4;16(1):10-11. doi: 10.1021/acsmedchemlett.4c00565. eCollection 2025 Jan 9.
本文引用的文献
1
Novel KRAS Inhibitors for Treating Non-Small-Cell Lung Cancer.用于治疗非小细胞肺癌的新型KRAS抑制剂
ACS Med Chem Lett. 2024 May 22;15(6):773-774. doi: 10.1021/acsmedchemlett.4c00217. eCollection 2024 Jun 13.
2
Unconventional strategy could be the future: From target to KRAS broad range treatment.非传统策略可能是未来的方向：从靶向治疗到KRAS广泛治疗。
Heliyon. 2024 Apr 18;10(9):e29739. doi: 10.1016/j.heliyon.2024.e29739. eCollection 2024 May 15.
3
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity.挖掘 KRAS 抑制对肿瘤免疫的治疗意义。
Cancer Cell. 2024 Mar 11;42(3):338-357. doi: 10.1016/j.ccell.2024.02.012.
4
Unveiling the role of KRAS in tumor immune microenvironment.揭示 KRAS 在肿瘤免疫微环境中的作用。
Biomed Pharmacother. 2024 Feb;171:116058. doi: 10.1016/j.biopha.2023.116058. Epub 2024 Jan 2.
5
Molecular pathology of non-small cell carcinoma.非小细胞癌的分子病理学
Histopathology. 2024 Jan;84(1):50-66. doi: 10.1111/his.15080. Epub 2023 Nov 7.
6
RAS-targeted cancer therapy: Advances in drugging specific mutations.RAS靶向癌症治疗：针对特定突变的药物研发进展
MedComm (2020). 2023 May 27;4(3):e285. doi: 10.1002/mco2.285. eCollection 2023 Jun.
Zotero 插件